A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

NCT01358877 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4804

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: 5-Fluorouracil
DRUG: Carboplatin
DRUG: Cyclophosphamide
DRUG: Docetaxel
DRUG: Doxorubicin
DRUG: Epirubicin
DRUG: Paclitaxel
DRUG: Pertuzumab
DRUG: Placebo
DRUG: Trastuzumab

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]
[object Object]